PLx Will More Prominently Disclose ‘Clinically Shown’ Claim Refers To Vazalore 325-mg Aspirin
Executive Summary
BBB National Programs’ appeals panel agrees with National Advertising Division that PLx should modify TV ad to clearly and conspicuously disclose that “clinically shown to cause fewer ulcers than plain aspirin” refers to Vazalore 325 mg and not 81-mg dose.
You may also be interested in...
Industry Self-Regulation Group Sends Questions About PLx Pharma’s Vazalore Claims To FTC
Over past year, PLx's Vazalore ad claimswere reviewed National Advertising Division before and after launch. As PLx appeals NAD’s post-launch review findings, NAD attorneys send questions about pre-launch claims to FTC.
PLx Pharma Irritated By Industry Self-Regulation Group’s Findings On Vazalore GI Comfort Claim
PLx disagrees with National Advertising Division’s recommendations following review on Bayer’s challenge of TV commercial and will appeal findings to National Advertising Review Board. NAD attorneys thank PLx’s “ voluntary participation” in SWIFT review but PLx makes clear it didn’t agree to a SWIFT process.
PLx Pharma Saturates Health Care Providers With Marketing For Liquid-Filled Vazalore Aspirin
PLx says Vazalore, only liquid-filled OTC aspirin in the US, had strong sales growth since launch in 30,000 stores. It plans second phase of rollout and promotions to expand outreach to cardiologists and patients.